Menopause represents one of the most under-addressed inflection points in skin aging. Driven primarily by a sharp decline in estrogen, menopause accelerates structural skin aging, alters hydration and elasticity and meaningfully impacts women’s confidence and wellbeing. New global survey data from Galderma, presented at IMCAS 2026, reveals a striking gap between what women experience, what they understand and when they act—creating a clear opportunity for education, earlier intervention and science-backed aesthetic solutions.
Deep dive: Menopause Goes Mainstream: Cara Kamenev, Stripes Beauty’s CEO, on a Bold Ulta Expansion
The Biology: How Estrogen Decline Reshapes Skin During Menopause
Estrogen plays a central role in maintaining skin health throughout adulthood. As women enter peri-menopause and menopause, estrogen levels fluctuate and then decline significantly, triggering cascading effects across the skin’s structure and function.
Key biological impacts include:
- Collagen and elastin loss:
Estrogen supports fibroblast activity and collagen synthesis. As estrogen declines, collagen degradation accelerates—research shows up to a 30% reduction in collagen within the first five years post-menopause. This leads directly to loss of firmness, increased wrinkle depth and reduced resilience. - Reduced elasticity and skin thickness:
Elastin fibers weaken and dermal thickness decreases, making skin more fragile and less able to recover from mechanical stress. - Decreased hyaluronic acid and hydration:
Estrogen helps regulate hyaluronic acid production. Lower levels result in diminished moisture retention, contributing to dryness, itchiness, and a dull appearance.
Together, these changes explain why menopause is often associated with sudden, noticeable shifts in skin quality—rather than the gradual aging women expect earlier in life.
The Lived Reality: What Women Experience—and How It Affects Wellbeing
Galderma’s global survey of more than 4,300 peri- and post-menopausal women aged 45–60 across nine countries underscores how widespread and impactful these changes are.
What women experience:
- An average of three skin changes since the onset of menopause
- Most common concerns:
- Lines and wrinkles: 59% on the face
- Loss of firmness and elasticity: 58% on the face
- Increased dryness: 56% on the face
- Duller skin tone: 40% on the face
- Overall severity of skin changes rated 6 out of 10
Emotional and social impact:
- 60% say menopause-related skin changes make them feel less attractive
- 57% feel anxious
- 55% feel less confident
- 46% report wanting to socialize less
These findings position menopause-related skin changes not as a cosmetic inconvenience, but as a quality-of-life issue with emotional and social consequences.
The Awareness Gap: Too Little, Too Late
Despite the prevalence of symptoms, awareness remains low—and arrives late.
- Over 50% of women learned about menopause’s impact on skin only by experiencing it themselves
- Most discovered this information in their 40s
- Over 30% would have preferred to learn about it in their 30s
- More than 50% are neutral or dissatisfied with their current knowledge
This delayed awareness has real consequences: it narrows the window for prevention and drives reactive, treatment-only behavior.
What Women Do Today—and What They Would Do Differently
When women do act, they are decisive—but often late.
- 49% currently use aesthetic treatments to treat menopause-related skin changes
- Only 26% use aesthetics for prevention
- Over 60% say they would have acted differently if they had known earlier about menopause’s impact on skin
Among available interventions—ranging from lifestyle changes to supplements—aesthetic treatments ranked highest in satisfaction, reinforcing their perceived effectiveness when women do engage.
Future consideration rates are strong:
- 47% would consider anti-wrinkle treatments
- 41% hyaluronic acid injectables
- 39% hyaluronic acid skin quality treatments
- 30% biostimulators
The Opportunity: Education, Earlier Intervention and Menopause-Inclusive Innovation
For beauty and aesthetics leaders, the implications are clear:
- Education is the unlock.
There is strong demand for earlier, clearer information—ideally before visible damage occurs. Brands that lead with credible education can expand the preventative market, not just compete for corrective treatments. - Prevention is underpenetrated.
The gap between treatment (49%) and prevention (26%) represents a major growth opportunity, especially for biostimulators and skin quality solutions that address collagen and elastin decline at the source. - Clinical relevance matters.
Galderma’s decision to include menopausal status in all injectable aesthetics clinical trials sets a new standard. Menopause-inclusive data strengthens claims, improves outcomes and builds trust with both clinicians and patients. - Menopause is not a niche—it’s a lifecycle moment.
With approximately 85% of aesthetic patients being female, menopause should be treated as a core planning lens across R&D, clinical strategy, education and portfolio design.
Menopause and Skin Aging: A Wake-Up Call for the Beauty Industry
Menopause accelerates skin aging through estrogen-driven losses in collagen, elastin and hydration—changes that are deeply felt but poorly understood until it’s too late. The data shows women are ready to act, wish they had acted sooner and respond positively to science-backed aesthetic solutions. For the beauty and aesthetics industry, menopause is no longer a silent phase—it’s a strategic opportunity hiding in plain sight.
